INBRAIN Neuroelectronics raises 46M€ in a funding round
The Catalan company, a spin-off from the CSIC and the ICN2, has raised said quantity in a round led by Imex.Xpand and will use it to accelerate the development of a graphene-based neuronal therapeutic interface.
The neurotechnology market is growing every year; their potential is currently reaching $1.000 million annually. InBrain Neuroelectronics, an innovative spin-off from the ICN2 and the CSIC focused on developing brain-computer interfaces for neurologic therapies, falls within this field, going against the likes of Precision Neuroscience or Neuralink, owned by Elon Musk.
Specifically, InBrain has developed a unique technology using graphene, a material extremely thin (one athom thick), flexible, and resistant, to decode and module high-precision neurological signals. Among all of its possibilities to use, one of the standouts is the potential for the treatment of neurological diseases like Parkinson's disease and epilepsy.
The funding round has been led by the investment arm of the Interuniversity Microelectronics Centre (IMEC), Imec.Xpand. Not only that, but they have also received both funding and resources from Merck, a pharmaceutical multinational with headquarters in Germany. This investment round brings the total funds raised to 68 million since the foundation of the company and will help with the translation of the InBrain platform to humane uses.
With this funding, there will be a possibility to advance in the security clinic trials of the bidirectional Brain-Computer Interfaces (BCI), a pioneering technology by InBrain to decode neurological signals during brain tumour resection surgery.
An intelligent and patient aware BCI therapeutics platform able to diagnose and treat real time in high resolution